Evogene (EVGN) - Total Liabilities

Latest as of September 2025: ILA8.83 Million ILA ≈ $23.68K USD

Based on the latest financial reports, Evogene (EVGN) has total liabilities worth ILA8.83 Million ILA (≈ $23.68K USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset growth rate of Evogene to track the company's year-over-year net asset growth rate.

Evogene - Total Liabilities Trend (2006–2024)

This chart illustrates how Evogene's total liabilities have evolved over time, based on quarterly financial data. See EVGN cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.

Evogene Competitors by Total Liabilities

The table below lists competitors of Evogene ranked by their total liabilities.

Company	Country	Total Liabilities
Desert Control AS OL:DSRT	Norway	Nkr5.90 Million
The GYM Group PLC LSE:GYM	UK	GBX474.20 Million
OLB Group Inc NASDAQ:OLB	USA	$6.88 Million
Recrusul S/A SA:RCSL3	Brazil	R$65.75 Million
Bang Overseas Limited NSE:BANG	India	Rs1.03 Billion
Aptose Biosciences Inc TO:APS	Canada	CA$25.79 Million
Clara Resources Australia Ltd AU:C7A	Australia	AU$903.05K

Liability Composition Analysis (2006–2024)

This chart breaks down Evogene's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see EVGN company net worth.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	4.92	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	7.74	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.34	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Evogene's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Evogene (2006–2024)

The table below shows the annual total liabilities of Evogene from 2006 to 2024.

Year	Total Liabilities	Change
2024-12-31	ILA25.03 Million ≈ $67.09K	+11.64%
2023-12-31	ILA22.42 Million ≈ $60.10K	+5.06%
2022-12-31	ILA21.34 Million ≈ $57.20K	+65.60%
2021-12-31	ILA12.88 Million ≈ $34.54K	-14.30%
2020-12-31	ILA15.03 Million ≈ $40.30K	+34.86%
2019-12-31	ILA11.15 Million ≈ $29.88K	+32.89%
2018-12-31	ILA8.39 Million ≈ $22.49K	+1.99%
2017-12-31	ILA8.22 Million ≈ $22.05K	-5.44%
2016-12-31	ILA8.70 Million ≈ $23.32K	-1.65%
2015-12-31	ILA8.84 Million ≈ $23.71K	-23.13%
2014-12-31	ILA11.50 Million ≈ $30.84K	-8.44%
2013-12-31	ILA12.56 Million ≈ $33.68K	-24.30%
2012-12-31	ILA16.60 Million ≈ $44.49K	-16.19%
2011-12-31	ILA19.80 Million ≈ $53.09K	-24.25%
2010-12-31	ILA26.14 Million ≈ $70.08K	+11.04%
2009-12-31	ILA23.54 Million ≈ $63.12K	-3.27%
2008-12-31	ILA24.34 Million ≈ $65.25K	+390.59%
2007-12-31	ILA4.96 Million ≈ $13.30K	+56.89%
2006-12-31	ILA3.16 Million ≈ $8.48K	--

About Evogene

TA:EVGN Israel Biotechnology

Market Cap

$4.44 Million

ILA1.66 Billion ILA

Market Cap Rank

#28792 Global

#422 in Israel

Share Price

ILA190.00

Change (1 day)

+8.57%

52-Week Range

ILA118.50 - ILA461.00

All Time High

ILA33620.00